Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lotensin

(Benazepril)

ApprovedSmall molecule

VValidus Pharmaceuticals

Lotensin is one of 53 small molecule programs targeting Albuminuria. It is currently in Approved.

4

Indications

10

Total Trials

0

Active Trials

52

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AlbuminuriaActive, not recruiting

Renal InsufficiencyActive, not recruiting

Peritoneal DialysisCompleted

Dilated CardiomyopathyCompleted

AlbuminuriaPreclinical

Active, not recruiting

Renal InsufficiencyPreclinical

Active, not recruiting

Peritoneal DialysisPreclinical

Completed

Dilated CardiomyopathyApproved

Completed

Competition

Competitive Landscape

38 competitors in Renal Insufficiency

#DrugCompanyPhaseTrials

Victoza

Jaypirca

Aliqopa

Gilenya

Retevmo

Genotropin

Zocor

OOrganon and Co

Cubicin

BBaxter Healthcare Corporation

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Lotensin

VValidus Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal insufficiency3 trials

Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency

Terminated·SSouthern Medical University, China·N/A·NCT00338091

Benazepril for Advanced Chronic Renal Insufficiency

Terminated·SSouthern Medical University, China·N/A·NCT00270426

Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency

Terminated·NNanfang Hospital, Southern Medical University·N/A·NCT00630708·309 enrolled

Type 2 Diabetes2 trials

Preventing Microalbuminuria in Type 2 Diabetes

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT00503152·612 enrolled

Preventing ESRD in Overt Nephropathy of Type 2 Diabetes

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT00494715·102 enrolled

Albuminuria1 trial

Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria

Completed·—·N/A·NCT00907374·46 enrolled

High Blood Pressure1 trial

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT00185120·152 enrolled

Dilated Cardiomyopathy1 trial

Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy

Completed·XXijing Hospital·Phase 4·NCT01917149·480 enrolled

2 more indications

Hypertensive1 trial

Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine

Completed·HHospital Universitario Pedro Ernesto·Phase 4·NCT01603940·30 enrolled

Peritoneal Dialysis1 trial

Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients

Completed·SSun Yat-sen University·N/A·NCT00721773·200 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 25, 1991

LOTENSIN

NDA NDA019851

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Benazepril. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Benazepril compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Benazepril. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019851). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Validus Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: VValidus Pharmaceuticals

Related News